WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 14'1801 Infant (under 12 months) mortality rate: 72
GDP / capita (US$): 21'0051 Child (under 5 years) mortality rate: 82

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 2'060  2'073  2'091  2'112  2'138  2'371  2'664  2'513 
Births 23  23  23  22  22  19  36  36 
Surviving infants 22  22  22  22  22  19  35  35 
Pop. less than 5 years 109  109  109  108  108  98  208  173 
Pop. less than 15 years 299  296  296  297  302  423  571  515 
Female 15-49 years 489  497  506  518  529  590  651  646 

Number of reported case

(Click for retrospective incidence data for Latvia)
Diphtheria 28  264 
Japanese encephalitis
Measles 21 
Mumps 41  10  1'949 
Pertussis 257  10  14  135  129 
Polio*
Rubella 62 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Latvia)
Vaccine year result method % card seen                                                
BCG          97  94  92  96  95  100 
DTP1          95  95  96  92  96  100 
DTP3          92  93  91  96  97  96 
HepB_BD          97  98  98 
HepB3          91  90  91  93  95  95 
Hib3          91  92  90  95  97  79 
JapEnc         
MCV          90  88  92  94  98  97 
MCV2          95  91  94  97  98  90 
PCV1          84  88  64 
PCV3          78  82 
Pol3          92  93  91  96  97  96 
Rota1         
Rota_last         
Rubella1          90  99  93  96  97 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Latvia)
BCG 97  94  92  96  95  99 
DTP1 95  95  96  98  99  99 
DTP3 92  93  91  96  97  96 
HepB3 91  90  91  93  95  95 
Hib3 91  92  90  95  97  79 
MCV 90  88  92  94  98  97 
PCV3 78  82 
Pol3 92  93  91  96  97  96 
Rota_last

Number of districts in the country 119  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 2-5 days; Yes
DTaPHibHepIPV 2, 4, 6, 12-15 months; Yes
DTaPHibIPV 2, 4, 6 months; Yes risk group
DTaPIPV 7 years; Yes
HPV 12 years (x3); Yes
HepB birth; 1, 2, 12-15 months; Yes for risk newborns or Y14 (x3 doses)
MMR 12-15 months; 7 years; Yes
Pneumo_conj 2, 4, 12-15 months; Yes
Td adults
TdIPV 14 years; Yes
Varicella 12-15 months; Yes

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR Yes  No  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2012-2014    2008-2010        NA 
Nº of districts with microplans that include activities to raise immunization coverage number   NA  NA  NA       

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR Yes  Yes  Yes         

System performance

Total number of districts in country number 119  119  33  33  33  33  33 
Nº districts with DTP3 coverage >=80% number     27  32  33  33  33 
% of districts with DTP3 coverage >=80% From 0 to 100%     82  97  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number     17    30     
% of districts with MCV1 coverage >=95% From 0 to 100%     52    91     

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND No  No  No         

Finance

Percentage of routine vaccines funded by Government From 0 to 100% 100  100  100  100    100  100 

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.